Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 13/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAPDH | P04406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6910415 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TSHRPOLBMEN1USP2 | |
| SCHEMBL22236587 | 0.85 | ALDH1A1 (0.49) | ALDH1A1TSHRPOLBMEN1USP2 | |
| SCHEMBL6048089 | 0.84 | TSHR (0.49) | ALDH1A1TSHRPOLBMEN1USP2 | |
| SCHEMBL5202139 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TSHRPOLBMEN1USP2 | |
| SCHEMBL14477070 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TSHRPOLBMEN1USP2 | |
| SCHEMBL15634412 | 0.83 | ALDH1A1 (0.43) | ALDH1A1TSHRPOLBMEN1USP2 | |
| SCHEMBL15127529 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TSHRPOLBMEN1USP2 | |
| SCHEMBL13151552 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TSHRPOLBMEN1USP2 | |
| SCHEMBL15127199 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TSHRPOLBMEN1USP2 | |
| SCHEMBL2785432 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TSHRPOLBMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0961775-B1 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6479463-B1 | USED TO TREAT AN INFECTION, AN INFESTATION, A NEOPLASM, OR AN AUTOIMMUNE DISEASE OR TO MODULATE ASPECTS OF THE IMMUNE SYSTEM, INCLUDING MODULATION OF TH1 AND TH2 | ICN PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020058635-A1 | Purine L-nucleosides, analogs and uses thereof | AVERETT DEVRON R (US) | 2002-05-16 | — | — | US | disclosed |
| EP-0961775-A2 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN Pharmaceuticals, Inc. (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998016184-A2 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058635-A1 | Purine L-nucleosides, analogs and uses thereof | PNP, NUDT1, TYMP | ALDH1A1 1668/4885TSHR 2233/4885POLB 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.